

A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SABR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

“Stablemates Trial”

Four more sites activate with Stablemates

We welcome the participation of these new sites:

Wake Forest Baptist Health - The team is led by A. William Blackstock Jr., M.D., Professor and Chair of Radiation Oncology.




University of Colorado - Tracey Schefter, M.D., is a radiation oncologist and Director of the Stereotactic Body Radiation Therapy (SBRT) program.



University of Cincinnati - PI Sandra Starnes, M.D., is Associate Professor of Surgery and Director of the Division of Thoracic Surgery.



Mayo Clinic Rochester - Shanda Blackmon, M.D., MPH, is Associate Professor of Thoracic Surgery.



Patient story: A Stablemates success

Fredna Sue Alter, age 88, was one of the first individuals enrolled on the Stablemates clinical trial. She recently returned to the UT Southwestern clinic in Dallas where she had been treated by Department Chair Hak Choy, M.D.


A former interior designer who enjoys playing golf, bridge, and walking her dog, Mrs. Alter got into a car accident last year, an unlucky event that may have ended up saving her life.

“The scan they did afterwards found two spots,” says Mrs. Alter. “They did two biopsies and the left one was positive [for cancer].”

Further tests revealed that Mrs. Alter had limited lung function due to chronic obstructive pulmonary disease, meaning she would be classified as a high-risk candidate for surgery. It also made her eligible for the Stablemates clinical trial. *(continued page 2)*



Jolt-Ca Study Accrual by Site



Note: On page 33 of protocol version 4.0, the website for determining a serious adverse event has been changed. Please make a note of the new website: <http://www.ut-southwestern.edu/research/research-administration/irb/study/reportable.html>. This will be updated in the next protocol amendment.

Subsite update

Active:

- Anne Arundel Medical Center
- Boston University
- CHUM-Notre Dame Hospital
- Henry Ford Health System
- Intermountain Medical Center
- Lifespan Oncology Clinical Research
- Mayo Clinic Rochester
- Medical College of Wisconsin
- Memorial Health University
- Ochsner Medical Center
- Ohio State University

- Ottawa
- Penn State (Mount Nittany Medical Center)
- Penrose Cancer Center
- SUNY
- Swedish Cancer Institute
- University of Cincinnati
- University of Colorado
- University of Kentucky
- University of Louisville Physicians
- University of Maryland
- UT Southwestern Medical Center
- University of Virginia

- Wake Forest
- West Clinic / University of Tennessee

Completed contracts and IRB approval:

- KUMC
- Meridian Health
- Providence Health and Services
- Thomas Jefferson University

Completed contracts:

- Karmanos Cancer Center
- UC San Diego

Patient story *continued*

“I saw both the surgeon and the radiation oncologist and each one gave me their pitch, it was up to me to choose,” she says. After being randomized to the radiation arm of the trial, she says, “I agreed. It was an absolute no-brainer to choose radiation over surgery. I knew I could always go back and have the surgery if [radiation] didn’t work.”

Her three radiation treatments were “totally painless,” she says. “I never had any ill effects at all.”

At nine months post-treatment, her former lesion is reduced to a small scar on imaging.

“Her disease appears to be under control,” says Dr. Choy. “She was a perfect patient for the study and she possibly benefitted from the trial by receiving an efficacious alternative treatment.”